Yoshito Itoh, Misato Tani, Ryo Takahashi, Koji Yamamoto
{"title":"Food-induced small bowel obstruction observed in a patient with inappropriate use of semaglutide.","authors":"Yoshito Itoh, Misato Tani, Ryo Takahashi, Koji Yamamoto","doi":"10.1007/s13340-024-00751-4","DOIUrl":null,"url":null,"abstract":"<p><p>We herein report a case of food-induced small bowel obstruction (FIBO) while using a glucagon-like peptide 1 receptor agonist (GLP1-RA), trying to lose weight due to distorted body image. The patient was a 30-year-old woman who was not obese (height 158 cm, weight 50 kg). She started taking an oral semaglutide, a GLP1-RA, and it was soon switched to weekly subcutaneous semaglutide because of ineffectiveness. More than 6 months after titrating up to 1.0 mg, she got drunk and chomped on a lot of scallops sandwiched between sheets of kelp, so-called \"kobujime\" in Japan, and half a day later complained of abdominal pain. Based on a finding of computed tomography at our emergency department, she was suspected of having a bowel obstruction and underwent laparoscopic surgery, which resulted in a diagnosis of small bowel obstruction by kelp. FIBO is rare, but it can become very severe once it happens. Although we cannot prove the direct pathophysiological effects of GLP1-RAs on FIBO in this particular case, GLP1-RAs have been reported to be one of the underlying risks of bowel obstruction based on epidemiological and basic research evidence; still, it is under-recognized. For example, the package inserts in Japan do not mention intestinal obstruction. We hope that the present report will prove helpful in paying attention to GLP1-RAs as a factor in bowel obstruction, including FIBO.</p>","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11512937/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetology International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13340-024-00751-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
We herein report a case of food-induced small bowel obstruction (FIBO) while using a glucagon-like peptide 1 receptor agonist (GLP1-RA), trying to lose weight due to distorted body image. The patient was a 30-year-old woman who was not obese (height 158 cm, weight 50 kg). She started taking an oral semaglutide, a GLP1-RA, and it was soon switched to weekly subcutaneous semaglutide because of ineffectiveness. More than 6 months after titrating up to 1.0 mg, she got drunk and chomped on a lot of scallops sandwiched between sheets of kelp, so-called "kobujime" in Japan, and half a day later complained of abdominal pain. Based on a finding of computed tomography at our emergency department, she was suspected of having a bowel obstruction and underwent laparoscopic surgery, which resulted in a diagnosis of small bowel obstruction by kelp. FIBO is rare, but it can become very severe once it happens. Although we cannot prove the direct pathophysiological effects of GLP1-RAs on FIBO in this particular case, GLP1-RAs have been reported to be one of the underlying risks of bowel obstruction based on epidemiological and basic research evidence; still, it is under-recognized. For example, the package inserts in Japan do not mention intestinal obstruction. We hope that the present report will prove helpful in paying attention to GLP1-RAs as a factor in bowel obstruction, including FIBO.
期刊介绍:
Diabetology International, the official journal of the Japan Diabetes Society, publishes original research articles about experimental research and clinical studies in diabetes and related areas. The journal also presents editorials, reviews, commentaries, reports of expert committees, and case reports on any aspect of diabetes. Diabetology International welcomes submissions from researchers, clinicians, and health professionals throughout the world who are interested in research, treatment, and care of patients with diabetes. All manuscripts are peer-reviewed to assure that high-quality information in the field of diabetes is made available to readers. Manuscripts are reviewed with due respect for the author''s confidentiality. At the same time, reviewers also have rights to confidentiality, which are respected by the editors. The journal follows a single-blind review procedure, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous. Single-blind peer review is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.